Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
05/2004
05/06/2004US20040087640 Administering by mouth; cyclooxygenase inhibitor; controlling particle size
05/06/2004US20040087638 Antidiabetic agents; antilipemic agents; anticholesterol agents; cardiovascular disorders; side effect reduction
05/06/2004US20040087637 Antiserotonine agents; central nervous system disorders
05/06/2004US20040087632 Controlling metabolism of lipids, cholesterol
05/06/2004US20040087630 Combinations
05/06/2004US20040087627 Decarboxylase inhibitors; cardiovascular diosrders; antidiabetic agents; anticancer agents; dietetics
05/06/2004US20040087625 Dietetics; antilipemic agents; anticholesterol agents; reducing triglycerides
05/06/2004US20040087624 Analgesics; antiinflammatory agents; immunology; bone disorders; neurodegradation diseases
05/06/2004US20040087604 Immunosuppressants; antiallergens
05/06/2004US20040087598 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-1,3-dihydoimidazo{1,2-a}pyrimidin-5(1h)one derivatives
05/06/2004US20040087597 Preventives and remedies for complications of diabetes
05/06/2004US20040087590 Novel biphenyl and biphenyl-like cannabinoids
05/06/2004US20040087588 Parp inhibitors
05/06/2004US20040087582 Anticaogulants; cardiovascular disorders; Factor x inhibitors; antiinflammatory agents
05/06/2004US20040087581 Heterocyclylalkylamines as muscarinic receptor antagonists
05/06/2004US20040087578 Pharmaceutical compositions containing carvedilol and hydrochlorothiazide
05/06/2004US20040087575 Therapeutic chromone compounds
05/06/2004US20040087552 Pyrrolidine modulators of ccr5 chemokine receptor activity
05/06/2004US20040087548 Anticancer agents and treating immune disorders
05/06/2004US20040087535 Administering a nitric oxide synthase gene in the form of naked dna; angiogenesis inhibitors
05/06/2004US20040087510 Cardiovascular diseases and disorders; sustained delivery of nitric oxide
05/06/2004US20040087504 Novel peptide sy
05/06/2004US20040087486 Inhibiting vascular occlusive events; reducing circulating count below normal levels without serious adverse consequence
05/06/2004US20040087484 Treating sexual dysfunction associated with hypertension; angiotensin receptor blocker with either antihypertensive agent or HMG-CoA reductase inhibitor
05/06/2004US20040087035 Using myeloproliferative leukemic inhibitory agents to treatment and/ or prevention platelet related thrombotic and vaso-occlusive disorder
05/06/2004US20040086999 Modified amino acid sequences for prevention and treatment of cancer, vision defects and inflammatory diseases
05/06/2004US20040086988 Enzyme catalyst; polypeptides; crystal structure
05/06/2004US20040086942 Comprises peptide mimetic which competes for binding site of immunoglobulin receptor and prevents and treats allergic disorders
05/06/2004US20040086905 Lipid-associated molecules
05/06/2004US20040086904 Identifying modulators which suppress synthesis of secreted and/or membrane protein for prevention and treatment of allergic,inflammatory, skin, cardiovascular, nervous system and cancer disorders
05/06/2004US20040086899 Compromises nuclelotide sequences coding polypeptides associated with elongation of fatty acid chains for treatment and prevention of skin, cardiovascular, inflammatory, gastrointestinal, respiratory system and bone disorders
05/06/2004US20040086877 Multi-mode directi memory access controller and method
05/06/2004US20040086565 Orally administering to once prior to sleep a dosage formulation comprising a biologically inert pellet having a drug layer, an outer rate controlling layer
05/06/2004US20040086525 Polynucleotide sequences of C. pneumoniae for use in preventing and treating Chlamydia infection
05/06/2004US20040086522 Strategies to prevent autoimmune disease by vaccination with vaccines based upon Epstein-Barr virus
05/06/2004US20040086514 Based on the finding of a specific Helicobacter pylori receptor in the human gastric epithelium; a glycolipid, lactotetraosylceramide, exclusively found in the human gastrointestinal tract
05/06/2004US20040086507 Antibody inhibiting vplf activity
05/06/2004US20040086505 Derived from human placenta
05/06/2004US20040086502 Has a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for said antigen
05/06/2004US20040086500 Murabutide, an analog of muramyl dipeptide, induces the production of cytokines or other factors not identified to date, which have a suppressor activity on HIV
05/06/2004US20040086487 Prevention or the treatment of congestive heart failure or myocardial ishchemia by administering a sphingosine kinase, or an analogue, fragment, or derivative thereof
05/06/2004EP1415994A1 Retinal pigmented epithelium derived neurotrophic factor
05/06/2004EP1415992A1 Diamine derivatives
05/06/2004EP1415990A1 Diazepan derivatives useful as factor X inhibitor
05/06/2004EP1415987A1 Nitrogenous aromatic ring compounds
05/06/2004EP1415986A1 Spiro compounds
05/06/2004EP1415983A1 5-amidino-n-(2-aminophenethyl)-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor
05/06/2004EP1415982A1 Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors
05/06/2004EP1415668A1 Remedies for brain ischemic diseases
05/06/2004EP1415663A1 Sustained release hgf hydrogel preparations
05/06/2004EP1415662A1 Homing autologous cells to a target zone in tissue for delivery of translocation stimulators
05/06/2004EP1415661A1 Homing of embryonic stem cells to a target zone in tissue for delivery of translocation stimulators
05/06/2004EP1415660A1 Homing donor cells to a target zone in tissue for delivery of translocation stimulators
05/06/2004EP1415659A1 BAFF, inhibitors thereof and their use in the modulation of the B-cell response
05/06/2004EP1414964A2 Vegf isoform
05/06/2004EP1414963A2 Lipid-associated molecules
05/06/2004EP1414961A2 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression
05/06/2004EP1414937A1 Hops extracts, method for the production and use
05/06/2004EP1414862A1 Anti-idiotypic antibodies of hla class i molecules and the use thereof in the preparation of compositions that are designed to inhibit vascular activation
05/06/2004EP1414855A2 Peptide inhibiting platelet derived growth factor (pdgf-bb) and fibroblast growth factor (bfgf) activity
05/06/2004EP1414853A2 Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon
05/06/2004EP1414849A2 Immune-modulating peptide
05/06/2004EP1414841A1 Oligonucleotide-containing pharmacological compositions and their use
05/06/2004EP1414837A1 Adenosine a3 receptor agonists
05/06/2004EP1414825A1 Thienopyrimidinediones and their use in the modulation of autoimmune disease
05/06/2004EP1414817A1 Substituted isoindoles and e use thereof
05/06/2004EP1414810A2 1,4-disubstituted benzo-fused cycloalkyl urea compounds
05/06/2004EP1414809A1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
05/06/2004EP1414806A1 Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
05/06/2004EP1414805A1 Indazole or indole derivatives, their use in human medicine and more particularly in cancerology
05/06/2004EP1414804A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors
05/06/2004EP1414802A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
05/06/2004EP1414790A1 Substituted n-acyl aniline derivatives, production and use thereof as medicaments
05/06/2004EP1414788A1 Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
05/06/2004EP1414785A1 Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
05/06/2004EP1414784A2 Amphiphilic star-like macromolecules for drug delivery
05/06/2004EP1414778A1 Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
05/06/2004EP1414775A2 Novel bicyclic and tricyclic cannabinoids
05/06/2004EP1414526A2 Antiangiogenic combination therapy for the treatment of cancer
05/06/2004EP1414523A2 Use of a lactate salt for the treatment and prophylaxis of atherosclerosis
05/06/2004EP1414486A2 Use of glp-2 in combination with another therapeutic agent in bone-related and nutrition-related disorders
05/06/2004EP1414471A2 Therapeutic agents comprising pro-apoptotic proteins
05/06/2004EP1414470A1 Micronutrient phosphates as dietary and health supplements
05/06/2004EP1414469A2 Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals
05/06/2004EP1414462A2 Treatment of renal fibrosis
05/06/2004EP1414456A1 Phenyl derivatives as factor xa inhibitors
05/06/2004EP1414455A1 Isoquinoline inhibitors of p38
05/06/2004EP1414450A1 (pyridinyl and pyrimidyl)trienoic acid derivatives as retinoid x receptor modulators
05/06/2004EP1414447A1 Use of thiazole derivatives for preparing a medicine for protecting mitochondria
05/06/2004EP1414444A1 Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists
05/06/2004EP1414440A1 N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
05/06/2004EP1414439A1 Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine
05/06/2004EP1414432A2 Methods of use for novel sulfur containing organic nitrate compounds
05/06/2004EP1414430A2 5-aminolevulinic acid and esters, in combination with another photosensitiser, as photosensitising agents in photochemotherapy, and their uses in treating wounds
05/06/2004EP1414428A1 Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs
05/06/2004EP1414426A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
05/06/2004EP1414410A1 Nanoparticulate formulations of fenofibrate
05/06/2004EP1414387A2 Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification
05/06/2004EP1414386A2 Canine cardiac diet
05/06/2004EP1280802B1 Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation